Plans to advance diverse pipeline of programs in oncology and metabolic diseases Anticipates key proof-of-concept readouts for TERN-701 (CML) and TERN-601 (obesity) in 2H24 Prioritizing capital ...
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts ELVN-001 continues to demonstrate a favorable ...
Imatinib marked a paradigm shift in CML treatment, offering significant improvements over previous therapies and reducing adverse effects. Despite imatinib's success, resistance and the need for ...
US regulators’ use of a speedy clearance pathway for a new frontline indication for asciminib for chronic myeloid leukemia (CML) has raised questions due to the number of medications already available ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results